Oncolytic rhabdovirus expressing IL12
US11590184B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Aug 9, 2017 |
| Grant date | Feb 28, 2023 |
| Priority date | — |
| Expiry date | Jan 9, 2040 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2760/20243
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed herein is an oncolytic recombinant Maraba virus whose genome comprises one or more nucleic acid sequences that, in combination, encode an interleukin-12 (IL12) protein or a functional portion thereof. A method for treating a cancer in a patient using the oncolytic recombinant Maraba virus is also disclosed. The present disclosure also provides a tumour cell infected with an oncolytic rhabdovirus whose genome comprises one or more nucleic acid sequences that, in combination, encode an interleukin-12 (IL12) protein or a functional portion thereof, for use as an infected cell vaccine (ICV) for the treatment of a cancer. A method for treating a cancer in a patient using the infected cell vaccine is also disclosed.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.